LANTHEUS HOLDINGS INC (LNTH)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for LNTH
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LNTH | Member; Director | 63 | ["Audit Committee Financial Expert", "financial sophistication", "Financial and legal background", "Extensive experience with radiopharmaceutical products", "Former Chief Financial Officer at Advanced Accelerator Applications S.A. (2003 to 2018)", "Former management consultant for Accenture and Gemini Consulting", "Director, Inventiva SA", "Director and Chairperson of the Audit Committee, Progenics Pharmaceuticals, Inc."] | ["Member", "Audit Committee", "Nominating and Corporate Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Heinz Mäusli Director since 2020 Independent 63 years old Committees: Audit Committee Nominating and Corporate Governance Committee Specific Expertise: Mr. Mäusli was chosen as a Director because of his financial and legal background and extensive experience with radiopharmaceutical products. Career Highlights: Former Chief Financial Officer (CFO), Advanced Accelerator Applications S.A., (2003 to 2018) Former management consultant for a number of strategy projects in both Europe and the United States for Accenture and Gemini Consulting, as well as independently Other Boards: Current Director, Inventiva SA Prior Director and Chairperson of the Audit Committee, Progenics Pharmaceuticals, Inc. (November 2019 until its acquisition by the Company) Education: Lic. oec., University of St.Gallen, Switzerland MBA, Columbia University